What changed
$AVGO — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ2 FY2026 (ends May) | reported Jun 03 | Rev $22.2B | EPS $2.44 vs $2.39 🟢 | Margin 48.6%
💡 Consensus appears to expect continued high growth, but even modest growth cannot support the current multiple. The market is pricing in a perfect scenario, while the historical base rate suggests multiples revert. My variant view is that the stock is priced for perfection with no room for error.
🏢 Business Quality: 8/10
📊 Valuation: rich — trailing P/E 37.4x vs sector peer band 7.4-18.7-46.2x and historical median 17.4x; reverse DCF implies -19.3% FCF growth; base DCF target...
🔮 Catalyst: Next earnings report or sector rotation
⚖️ Avoid: The risk/reward is severely negative, with the stock priced for perfection and a base case offering no upside.